Cost-Effectiveness of Various Interventions for Newly Diagnosed Diabetic Macular Edema – Corrected Proof
Objective: Anti–vascular endothelial growth factor therapies have revolutionized the treatment of clinically significant diabetic macular edema (CSDME); yet these agents are expensive, and whether they are cost-effective is unclear. The purpose of this study is to determine the most cost-effective treatment option for patients with newly diagnosed CSDME: focal laser photocoagulation alone (L), focal laser plus intravitreal ranibizumab (L+R), focal laser plus intravitreal bevacizumab (L+B), or focal laser plus intravitreal triamcinolone (L+T) injections.Design: Cost-effectiveness analysis.Participants: Hypothetical cohort of 57-year-old patients with newly diagnosed CSDME.Methods: By using a Markov model with a 25-year time horizon, we compared the incremental cost-effectiveness of (Read more...)